| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Anna Partyka, Grażyna Chłoń-Rzepa, Anna Wasik, Magdalena Jastrzębska-Więsek, Adam Bucki, Marcin Kołaczkowski, Grzegorz Satała, Andrzej J Bojarski, Anna Wesołowsk. Antidepressant- and anxiolytic-like activity of 7-phenylpiperazinylalkyl-1,3-dimethyl-purine-2,6-dione derivatives with diversified 5-HT₁A receptor functional profile. Bioorganic & medicinal chemistry. vol 23. issue 1. 2015-10-22. PMID:25435254. |
the study allowed us to identify some potent 5-ht1a receptor ligands with additional moderate affinity for 5-ht2a, 5-ht7 and dopamine d2 receptors. |
2015-10-22 |
2023-08-13 |
mouse |
| Melissa A Silverman, Jonathan G Leung, Kathryn M Scha. Aripiprazole-associated hiccups: a case and closer look at the association between hiccups and antipsychotics. Journal of pharmacy practice. vol 27. issue 6. 2015-09-30. PMID:25107419. |
aripiprazole's pharmacologic properties (including dopamine 2 and 5-hydroxytryptamine 1a [5ht1a] receptor partial agonism and 5ht2a receptors antagonism) may be associated with the onset of hiccups. |
2015-09-30 |
2023-08-13 |
Not clear |
| Xin Peng, Qi Wang, Yogesh Mishra, Jinbin Xu, David E Reichert, Maninder Malik, Michelle Taylor, Robert R Luedtke, Robert H Mac. Synthesis, pharmacological evaluation and molecular modeling studies of triazole containing dopamine D3 receptor ligands. Bioorganic & medicinal chemistry letters. vol 25. issue 3. 2015-09-15. PMID:25556097. |
affinity at dopamine d4 and serotonin 5-ht1a receptors was also determined. |
2015-09-15 |
2023-08-13 |
human |
| Darakhshan J Halee. 5-HT1A receptor-dependent control of nigrostriatal dopamine neurotransmission in the pharmacotherapy of Parkinson's disease and schizophrenia. Behavioural pharmacology. vol 26. issue 1-2. 2015-09-03. PMID:25503261. |
5-ht1a receptor-dependent control of nigrostriatal dopamine neurotransmission in the pharmacotherapy of parkinson's disease and schizophrenia. |
2015-09-03 |
2023-08-13 |
Not clear |
| Darakhshan J Halee. 5-HT1A receptor-dependent control of nigrostriatal dopamine neurotransmission in the pharmacotherapy of Parkinson's disease and schizophrenia. Behavioural pharmacology. vol 26. issue 1-2. 2015-09-03. PMID:25503261. |
this review concerns the role of 5-ht1a receptors in the modulation of nigrostriatal dopamine neurotransmission, with the aim of providing guidelines for future research to improve pharmacotherapy. |
2015-09-03 |
2023-08-13 |
Not clear |
| Darakhshan J Halee. 5-HT1A receptor-dependent control of nigrostriatal dopamine neurotransmission in the pharmacotherapy of Parkinson's disease and schizophrenia. Behavioural pharmacology. vol 26. issue 1-2. 2015-09-03. PMID:25503261. |
the current state of knowledge suggests that drugs simultaneously targeting dopamine d2 and 5-ht1a receptors may improve pharmacotherapy for schizophrenia and parkinson's disease. |
2015-09-03 |
2023-08-13 |
Not clear |
| Darakhshan J Halee. 5-HT1A receptor-dependent control of nigrostriatal dopamine neurotransmission in the pharmacotherapy of Parkinson's disease and schizophrenia. Behavioural pharmacology. vol 26. issue 1-2. 2015-09-03. PMID:25503261. |
drugs acting exclusively through dopamine d2 and 5-ht1a receptors are highly needed to validate the potential role of 5-ht1a receptors in improving therapeutics for parkinson's disease and schizophrenia. |
2015-09-03 |
2023-08-13 |
Not clear |
| Zeng Li, Jiye Huang, Haifeng Sun, Shengbin Zhou, Lin Guo, Yu Zhou, Xuechu Zhen, Hong Li. Design, synthesis and evaluation of benzo[a]thieno[3,2-g]quinolizines as novel l-SPD derivatives possessing dopamine D1, D2 and serotonin 5-HT1A multiple action profiles. Bioorganic & medicinal chemistry. vol 22. issue 21. 2015-07-22. PMID:25308766. |
design, synthesis and evaluation of benzo[a]thieno[3,2-g]quinolizines as novel l-spd derivatives possessing dopamine d1, d2 and serotonin 5-ht1a multiple action profiles. |
2015-07-22 |
2023-08-13 |
Not clear |
| Zeng Li, Jiye Huang, Haifeng Sun, Shengbin Zhou, Lin Guo, Yu Zhou, Xuechu Zhen, Hong Li. Design, synthesis and evaluation of benzo[a]thieno[3,2-g]quinolizines as novel l-SPD derivatives possessing dopamine D1, D2 and serotonin 5-HT1A multiple action profiles. Bioorganic & medicinal chemistry. vol 22. issue 21. 2015-07-22. PMID:25308766. |
a novel scaffold derived from l-spd with a substituted thiophene group in the d ring were designed, synthesized, and evaluated for their binding affinities at dopamine (d1, d2 and d3) and serotonin (5-ht1a and 5-ht2a) receptors. |
2015-07-22 |
2023-08-13 |
Not clear |
| Pia Baldinger, Andreas Hahn, Markus Mitterhauser, Georg S Kranz, Marion Friedl, Wolfgang Wadsak, Christoph Kraus, Johanna Ungersböck, Annette Hartmann, Ina Giegling, Dan Rujescu, Siegfried Kasper, Rupert Lanzenberge. Impact of COMT genotype on serotonin-1A receptor binding investigated with PET. Brain structure & function. vol 219. issue 6. 2015-07-07. PMID:23928748. |
given the close interactions between serotonergic and dopaminergic neurotransmission, we investigated whether a common single-nucleotide-polymorphism of the catechol-o-methyltransferase (comt) gene (val158met or rs4680) coding for a key enzyme of the dopamine network that is associated with the pathogenesis of mood disorders and antidepressant treatment response, directly affects 5-ht1a receptor binding potential. |
2015-07-07 |
2023-08-12 |
human |
| Per Svenningsson, Carl Rosenblad, Karolina Af Edholm Arvidsson, Klas Wictorin, Charlotte Keywood, Bavani Shankar, David A Lowe, Anders Björklund, Håkan Widne. Eltoprazine counteracts l-DOPA-induced dyskinesias in Parkinson's disease: a dose-finding study. Brain : a journal of neurology. vol 138. issue Pt 4. 2015-06-16. PMID:25669730. |
simultaneous activation of 5-ht1a and 5-ht1b receptors effectively blocks l-dopa-induced dyskinesias in animal models of dopamine depletion, justifying a clinical study with eltoprazine, a 5-ht1a/b receptor agonist, against l-dopa-induced dyskinesias in patients with parkinson's disease. |
2015-06-16 |
2023-08-13 |
Not clear |
| Philip D Harve. The clinical utility of lurasidone in schizophrenia: patient considerations. Neuropsychiatric disease and treatment. vol 11. 2015-05-21. PMID:25995636. |
in addition to full antagonist activity at the dopamine d2 (ki, 1 nm) and serotonin 5-ht2a (ki, 0.5 nm) receptors, the pharmacodynamic profile of lurasidone is notable for its high affinity for serotonin 5-ht7 receptors (0.5 nm) and its partial agonist activity at 5-ht1a receptors (ki, 6.4 nm). |
2015-05-21 |
2023-08-13 |
Not clear |
| Rui Zhao, Weijian Lu, Xing Fang, Lin Guo, Zhi Yang, Na Ye, Jiahao Zhao, Zhili Liu, Jia Jia, Longtai Zheng, Bin Zhao, Ao Zhang, Xuechu Zhe. (6aR)-11-amino-N-propyl-noraporphine, a new dopamine D2 and serotonin 5-HT1A dual agonist, elicits potent antiparkinsonian action and attenuates levodopa-induced dyskinesia in a 6-OHDA-lesioned rat model of Parkinson's disease. Pharmacology, biochemistry, and behavior. vol 124. 2015-05-19. PMID:24955866. |
(6ar)-11-amino-n-propyl-noraporphine, a new dopamine d2 and serotonin 5-ht1a dual agonist, elicits potent antiparkinsonian action and attenuates levodopa-induced dyskinesia in a 6-ohda-lesioned rat model of parkinson's disease. |
2015-05-19 |
2023-08-13 |
rat |
| Chris A Oosterhof, Mostafa El Mansari, Pierre Blie. Acute effects of brexpiprazole on serotonin, dopamine, and norepinephrine systems: an in vivo electrophysiologic characterization. The Journal of pharmacology and experimental therapeutics. vol 351. issue 3. 2015-02-17. PMID:25225185. |
using electrophysiologic techniques, the present study assessed the in vivo action of brexpiprazole on serotonin (5-ht) receptor subtypes 5-ht1a, 5-ht1b, and 5-ht2a; dopamine (da) d2 autoreceptors, and α1- and α2-adrenergic receptors. |
2015-02-17 |
2023-08-13 |
Not clear |
| Margherita Brindisi, Stefania Butini, Silvia Franceschini, Simone Brogi, Francesco Trotta, Sindu Ros, Alfredo Cagnotto, Mario Salmona, Alice Casagni, Marco Andreassi, Simona Saponara, Beatrice Gorelli, Pia Weikop, Jens D Mikkelsen, Jorgen Scheel-Kruger, Karin Sandager-Nielsen, Ettore Novellino, Giuseppe Campiani, Sandra Gemm. Targeting dopamine D3 and serotonin 5-HT1A and 5-HT2A receptors for developing effective antipsychotics: synthesis, biological characterization, and behavioral studies. Journal of medicinal chemistry. vol 57. issue 22. 2015-01-27. PMID:25343529. |
targeting dopamine d3 and serotonin 5-ht1a and 5-ht2a receptors for developing effective antipsychotics: synthesis, biological characterization, and behavioral studies. |
2015-01-27 |
2023-08-13 |
Not clear |
| Margherita Brindisi, Stefania Butini, Silvia Franceschini, Simone Brogi, Francesco Trotta, Sindu Ros, Alfredo Cagnotto, Mario Salmona, Alice Casagni, Marco Andreassi, Simona Saponara, Beatrice Gorelli, Pia Weikop, Jens D Mikkelsen, Jorgen Scheel-Kruger, Karin Sandager-Nielsen, Ettore Novellino, Giuseppe Campiani, Sandra Gemm. Targeting dopamine D3 and serotonin 5-HT1A and 5-HT2A receptors for developing effective antipsychotics: synthesis, biological characterization, and behavioral studies. Journal of medicinal chemistry. vol 57. issue 22. 2015-01-27. PMID:25343529. |
combination of dopamine d3 antagonism, serotonin 5-ht1a partial agonism, and antagonism at 5-ht2a leads to a novel approach to potent atypical antipsychotics. |
2015-01-27 |
2023-08-13 |
Not clear |
| Michelle R Lofwall, Paul A Nuzzo, Charles Campbell, Sharon L Wals. Aripiprazole effects on self-administration and pharmacodynamics of intravenous cocaine and cigarette smoking in humans. Experimental and clinical psychopharmacology. vol 22. issue 3. 2015-01-26. PMID:24467369. |
aripiprazole is a partial agonist at dopamine (d2) and serotonin (5-ht1a) receptors and 5-ht2 antagonist. |
2015-01-26 |
2023-08-12 |
human |
| Kate McKeag. Aripiprazole: a review of its use in the treatment of manic episodes in adolescents with bipolar I disorder. CNS drugs. vol 28. issue 2. 2015-01-13. PMID:24399490. |
unlike other currently available atypical antipsychotics that primarily have varying degrees of dopamine d2 receptor antagonism, aripiprazole is a partial agonist at d2 and serotonin 5-ht1a receptors, which may explain differences in tolerability profiles. |
2015-01-13 |
2023-08-12 |
human |
| Eiji Kirin. Profile of aripiprazole in the treatment of bipolar disorder in children and adolescents. Adolescent health, medicine and therapeutics. vol 5. 2014-12-04. PMID:25473324. |
aripiprazole acts as a serotonin 5-ht2a receptor antagonist, as well as a partial agonist of the serotonin 5-ht1a and dopamine d2 receptors. |
2014-12-04 |
2023-08-13 |
Not clear |
| Arunachalam Muthuraman, Nirmal Singh, Amteshwar Singh Jaggi, Muthusamy Rames. Drug therapy of neuropathic pain: current developments and future perspectives. Current drug targets. vol 15. issue 2. 2014-10-09. PMID:24093749. |
the review also gives an insight into various pharmacological agents with potential neuropathic pain attenuating properties in experimental models that include nsaids, corticosteroids, ion channel blockers (ca(2+), na(+), k(+), and trp channel); ion exchange modulators (nce and nhe); ion/molecule transport modulators (nkcc-1 and glycine); receptor modulators (kinin, histamine, 5-ht1a, dopamine, alpha & beta adrenergic, purinergic, excitatory amino acid, sigma, orl1, endothelin, melanocortin, ephrin and par); enzyme inhibitors (cytosolic kinase, metalloproteinase, protease, vasopeptidase, d-amino acid oxidase, fatty acid amide hydrolase, aldose reductase and sorbitol dehydrogenase); other ligands (age, rages, neuropeptides, neurotrophic factor, complement cascade, cytokine, glial cell & gap junction, nitrous oxide, growth factor, cell adhesion molecule and neuronal sprouting molecule). |
2014-10-09 |
2023-08-12 |
Not clear |